Jiangsu Hengrui Pharmaceuticals at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Jiangsu Hengrui Pharmaceuticals brings 2 presentations to ObesityWeek 2026 in National Harbor. Its posters report phase 3 HARBOR-1 results for HRS-7535 in weight management among Chinese adults with overweight or obesity, plus a subgroup analysis of the drug's effect on glycemic status in prediabetes.

OrganizationObesityWeek 2026 Attendance
Large pharma
Pharmaceutical company whose obesity pipeline includes HRS-7535, an oral GLP-1 receptor agonist in phase 3.
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
HRS-7535 Effect on Glycaemic Status in Prediabetes: HARBOR-1 Subgroup Analysis
Interventional and clinical studiesObesity pharmacotherapy and drug development

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Jiangsu Hengrui Pharmaceuticals

Tell us what you sell and we’ll find the people at Jiangsu Hengrui Pharmaceuticals most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction